The Online Investor

Slideshow Mergers & Acquisitions

By The Online Investor Staff, updated Wed., Feb. 26, 4:50 PM

Slide #25. Eli Lilly and Company Dermira, Inc.

Acquirer: Eli Lilly and Company (LLY)
Acquiree: Dermira, Inc. (DERM)
Details: Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Dermira, Inc. (NASDAQ: DERM). The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity that is being evaluated in a Phase 3 clinical development program for the treatment of moderate-to-severe atopic dermatitis in adolescent and adult patients, ages 12 years and older. The acquisition of Dermira also expands Lilly's portfolio of marketed dermatology medicines with the addition of QBREXZA (glycopyrronium), a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating).

Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s human pharmaceutical products include: diabetes and other endocrinology products, immunology products, neuroscience products, oncology products, and other products. Co.'s diabetes and other endocrinology products include: Baqsimi® and Basaglar®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta® and Emgality®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux® and Verzenio®. Co.'s other products include: Cialis®.

Eli Lilly SEC Filing Email Alerts Service


Open the LLY Page at The Online Investor »

Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s human pharmaceutical products include: diabetes and other endocrinology products, immunology products, neuroscience products, oncology products, and other products. Co.'s diabetes and other endocrinology products include: Baqsimi® and Basaglar®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta® and Emgality®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux® and Verzenio®. Co.'s other products include: Cialis®.

Eli Lilly SEC Filing Email Alerts Service


Open the DERM Page at The Online Investor »

Company Name: 
Lilly (Eli) & Co
Stock buyback: 
LLY buyback
Website: 
www.lilly.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding LLY: 
105
Total Market Value Held by ETFs: 
$10.63B
Total Market Capitalization: 
$132.64B
% of Market Cap. Held by ETFs: 
8.02%
Company Name: 
Dermira Inc
Website: 
www.dermira.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding DERM: 
22
Total Market Value Held by ETFs: 
$81.94M
Total Market Capitalization: 
$1.02B
% of Market Cap. Held by ETFs: 
8.02%
 

Quotes delayed 20 minutes


Mergers & Acquisitions Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.